Bernstein SocGen Group analyst Jeffrey Walch upgraded Summit Therapeutics plc (NASDAQ: SMMT) from Underperform to Market Perform with a price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE